| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6465504 | NOVARTIS | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr, 2019
(5 years ago) | |
Jadenu Sprinkle is owned by Novartis.
Jadenu Sprinkle contains Deferasirox.
Jadenu Sprinkle has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Jadenu Sprinkle are:
- US6465504
Jadenu Sprinkle was authorised for market use on 18 May, 2017.
Jadenu Sprinkle is available in granule;oral dosage forms.
The generics of Jadenu Sprinkle are possible to be released after 23 July, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-241) | Jul 24, 2022 |
| M(M-239) | Dec 12, 2021 |
| M(M-263) | Jul 23, 2023 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 18 May, 2017
Treatment: NA
Dosage: GRANULE;ORAL
More Information on Dosage
JADENU SPRINKLE family patents
